



Substitute for form 1449A/PTO  
(Modified)

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	10/805,683
Filing Date	March 10, 2004
First Named Inventor	SPANGLER, Charles W.
Art Unit	1616
Examiner Name	Not Yet Assigned
Attorney Docket Number	A-72170-1

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	2003/0105070 A1	06-05-2003	Nickel et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Country Code* Number* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	1*
	B1					

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1*
C1		ACHILEFU, S., et al., "Novel Receptor-Targeted Fluorescent Contrast Agents for In Vivo Tumor Imaging", Investigative Radiology, 2000, 35(8):479-485.	
C2		BECKER, A., et al., "Macromolecular Contrast Agents for Optical Imaging of Tumors: Comparison of Indotricarbocyanine-labeled Human Serum Albumin and Transferrin", Photochemistry and Photobiology, 2000, 72(2):234-241.	
C3		BECKER, A., et al., "Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands", Nature Biotechnology, 2001, 19:327-331.	
C4		FISHER, W.G., et al., "Simultaneous Two-Photon Activation of Type-I Photodynamic Therapy Agents", Photochemistry and Photobiology, 1997, 66(2):141-155.	
C5		FLANAGAN JR., J.H., et al., "Functionalized Tricarbocyanine Dyes as Near-Infrared Fluorescent Probes for Biomolecules", Bioconjugate Chem., 1997, 8:751-756.	
C6		FRECHET, J.M.J., et al., "Dendrimers and Other Dendritic Polymers", Chichester: John Wiley & Sons, Ltd., 2001.	
C7		GODAR, D.E., "Light and Death: Photons and Apoptosis", J. Investigative Dermatology Symp. Proc., 1999, 11:17-23.	
C8		GOYAN, R.L., et al., "Near-Infrared Two Photon Excitation of Photoporphyrin IX: Photodynamics and Photoproduct Generation", Photochemistry and Photobiology, 2000, 72(6):821-827.	
C9		KAROTKI, A., et al., "Efficient Singlet Oxygen Generation Upon Two-Photon Excitation of New Porphyrin With Enhanced Nonlinear Absorption", IEEE J. Selected Topics in Quantum Electronics, 2001, 7(6):971-975.	
C10		KESSEL, D., et al., "Determinants of PDT-Induced Apoptosis", Prog. Biomed. Optics, Proc. SPIE, 2001, 4248:132.	
C11		LICHA, K., et al., "Synthesis, Characterization, and Biological Properties of Cyanine-labeled Somatostatin Analogues as Receptor-Targeted Fluorescent Probes", Bioconjugate Chem., 2001, 12:44-50.	
C12		LICHA, K., et al., "Hydrophilic Cyanine Dyes as Contrast Agents for Near-Infrared Tumor Imaging: Synthesis, Photophysical Properties and Spectroscopic In Vivo Characterization", Photochemistry and Photobiology, 2000, 72(3):392-398.	
C13		MESHALKIN, Y.P., et al., "Two-photon excitation of aluminium phthalocyanines", Quantum Electronics, 1999, 29(12):1066-1068.	

Examiner Signature	/Leah Schlientz/	Date Considered	11/10/2008
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Substitute for form 1449A/PTO (Modified)				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/805,683
				Filing Date	March 10, 2004
				First Named Inventor	SPANGLER, Charles W.
				Art Unit	1616
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	A-72170-1

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Citation No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	C14	OLEINICK, N.L., et al., "PDT-induced apoptosis: What are the critical molecular targets?" Prog. Biomed. Optics Proc. SPIE, 2001, 4248:132-137.			
	C15	OLEINICK, N.L., et al., "Stress-activated signaling responses leading to apoptosis following photodynamic therapy", Prog. Biomed. Optics Proc. SPIE, 1998, 3247:82-88.			
	C16	SPANGLER, C.W., et al., "Nanophotonic Ensembles for targeted Multi-photon Photodynamic Therapy", Nanobiophotonics and Biomedical Applications, Proc. SPIE, 2004, 5331:84-91.			
	C17	WACHTER, E.A., et al., "Simultaneous Two-Photon Excitation of Photodynamic Therapy Agents", Proc. SPIE, 1998, 3269:68-75.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/

Examiner Signature	/Leah Schlientz/	Date Considered	11/10/2008
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2